#antineuroinflammatory
November 2, 2026 at 9:31 AM
IMMUNOCHEM THERAPEUTICS LLC received a $2.48M federal grant. Purpose: (NO IDC) ADVANCING AN EXPERIMENTAL ANTINEUROINFLAMMATORY DRUG TOWARD A PHASE 2A CLINICAL TRIAL IN TRAUMATIC BRAIN INJURY...

https://www.narrowit.com/award?awardId=HT9425261E262
#Usaspending #FederalAwards #Grants #Defense
$2,475,620 - Grant - IMMUNOCHEM THERAPEUTICS LLC From Department of Defense
IMMUNOCHEM THERAPEUTICS LLC received a $2,475,620 federal grant from Department of Defense. (NO IDC) ADVANCING AN EXPERIMENTAL ANTINEUROINFLAMMATORY DRUG TOWARD A PHASE 2A CLINICAL TRIAL IN TRAUMATIC BRAIN INJURY
www.narrowit.com
August 1, 2026 at 1:17 PM
Additionally, 3 compounds demonstrated significant antineuroinflammatory effects in murine microglial cells.
September 2, 2025 at 9:19 PM